Daridorexant Earns FDA Breakthrough Designation in Pediatric Insomnia

The FDA granted Breakthrough Therapy designation to daridorexant, a dual orexin receptor antagonist, for treating pediatric insomnia disorder based on positive phase 2 trial results showing significant sleep time improvement and good tolerability.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it.